Wockhardt Jumps on Positive Trial Results for Miqnaf Drug

Wockhardt shares surged 7.45% to ?1,435 following the publication of positive Phase 3 clinical trial results for its novel antibiotic Miqnaf (nafithromycin).

Miqnaf, discovered and developed internally by Wockhardt, is the company’s third new drug emerging from its in-house research pipeline. It targets community-acquired bacterial pneumonia (CABP) and marks the first new macrolide class antibiotic to be developed in over 30 years. The drug has also been granted the Qualified Infectious Disease Product (QIDP) designation by the US FDA, based on earlier global Phase 1 and 2 trials.

The Phase 3 trial involved approximately 500 patients and demonstrated that Miqnaf was non-inferior to moxifloxacin, with over 90% of patients showing clinical improvement within 3–4 days of starting treatment.

Also Read: Syngene Advances Novel Vascular Calcification Inhibitor API

Designed as a once-daily, three-day oral treatment, Miqnaf aims to combat growing antibiotic resistance. According to the Indian Council of Medical Research, macrolide resistance reached nearly 75% in 2023, underlining the urgent need for new therapies like Miqnaf.

Wockhardt, a global pharmaceutical and biotechnology firm focused on research, recently reported a consolidated net loss of ?90 crore for Q1 FY2026, widening from a ?14 crore loss in the same quarter last year. Revenue for the quarter stood at ?738 crore, registering a marginal year-on-year decline of 0.14%.